Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-08-15

Sasya Dronavalli

Assistant Professor

Faculty Researcher

COM | Internal Med Hem-Onc

9 pubs

  • Cytomegalovirus Infections
  • Cytomegalovirus
  • Multiple Myeloma
  • Virus Activation
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome

Biography and Research Information

OverviewAI-generated summary

Sasya Dronavalli's research focuses on the clinical outcomes and risk factors associated with cytomegalovirus (CMV) reactivation in patients undergoing treatment for multiple myeloma. This includes investigating CMV reactivation in patients treated with teclistamab, a bispecific antibody, examining both clinical outcomes and identified risk factors. Dronavalli's work also addresses disseminated Bartonella henselae infection in patients with relapsed or refractory multiple myeloma following autologous stem cell transplantation. Dronavalli has 8 total publications and collaborates with researchers at the University of Arkansas for Medical Sciences, including Syed Naqvi and Fenghuang Zhan.

Metrics

  • Publications: 9

Selected Publications

  • The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)
    Research Square DOI OpenAlex
  • Long term follow up of multiple myeloma patients achieving MRD negativity at 10 <sup>-6</sup> . (2026)
    Journal of Clinical Oncology DOI OpenAlex
  • Real-world analysis of CRS and ICANS following tarlatamab and its association with survival in patients with SCLC. (2026)
    Journal of Clinical Oncology DOI OpenAlex
  • Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)
    Journal of Clinical Oncology DOI OpenAlex
  • Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)
    Journal of Clinical Oncology DOI OpenAlex
  • Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
    Blood Cancer Journal DOI OpenAlex
  • Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025)
    Blood DOI OpenAlex
  • Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell Transplantation (2025)
    Cureus DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

24 Collaborators 4 Institutions 2 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics